Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum

Teva Pharmaceutical Industries Ltd TEVA stock is trading higher on Wednesday after the company's first- quarter 2025 financial results. Here are the details. Teva reported revenue of $3.89 billion, up 5$4.00 billion, according to Benzinga Pro. The increase was driven by higher revenues from Austedo in the U.S. segment. Austedo's worldwide revenues were $411 million in Q1 2025, an increase of 39% in local currency terms compared to Q1 2024. U.S. Austedo revenues ...